Answers are grounded in this paper and cite their sources.
Human African trypanosomiasis (HAT) is a fatal infectious disease caused by the eukaryotic pathogen Trypanosoma brucei ( Tb ). Available treatments are difficult to administer and have significant safety issues. S -Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the parasite polyamine biosynthetic pathway. Previous attempts to develop Tb AdoMetDC inhibitors into anti-HAT therapies failed due to poor brain exposure. Here, we describe a large screening campaign of two small-molecule libraries (∼400,000 compounds) employing a new high-throughput (∼7 s per sample) mass spectrometry-based assay for AdoMetDC activity. As a result of primary screening, followed by hit confirmation and validation, we identified 13 new classes of reversible Tb AdoMetDC inhibitors with low-micromolar potency (IC 50 ) against both Tb AdoMetDC and T. brucei parasite cells. The majority of these compounds were >10-fold selective against the human enzyme. Importantly, compounds from four classes demonstrated high propensity to cross the blood–brain barrier in a cell monolayer assay. Biochemical analysis demonstrated that compounds from eight classes inhibited intracellular Tb AdoMetDC in the parasite, although evidence for a secondary off-target component was also present. The discovery of several new Tb AdoMetDC inhibitor chemotypes provides new hits for lead optimization programs aimed to deliver a novel treatment for HAT.
No takes yet. Share an insight, caveat, or question.
Volkov et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: